Wuxi Biologics readies Hong Kong relisting

Wuxi PharmaTech is looking to relist its biologic arm in Hong Kong after the group was taken private through a management buyout in late 2015.
Wuxi Pharma plans to list its biologic arm in Hong Kong, 10 years after its New York listing in 2007
Wuxi Pharma plans to list its biologic arm in Hong Kong, 10 years after its New York listing in 2007
January 06, 2017

Shanghai-headquartered biopharmaceutical firm Wuxi PharmaTech has taken the first step to relist its biologics unit in Hong Kong after filing a listing application with the city’s stock exchange this week.

¬ Haymarket Media Limited. All rights reserved.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Share our publication on social media
Share our publication on social media